XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: A retrospective study of the anatolian society of medical oncology

Simple item page
dc.contributor.authorDuran A.O.
dc.contributor.authorKaraca H.
dc.contributor.authorBesiroglu M.
dc.contributor.authorBayoglu I.V.
dc.contributor.authorMenekse S.
dc.contributor.authorYapici H.S.
dc.contributor.authorYazilitas D.
dc.contributor.authorBahceci A.
dc.contributor.authorUysal M.
dc.contributor.authorSevinc A.
dc.contributor.authorHacibekiroglu I.
dc.contributor.authorAksoy A.
dc.contributor.authorTanriverdi O.
dc.contributor.authorArpaci E.
dc.contributor.authorInanc M.
dc.contributor.authorDane F.
dc.contributor.authorOzkan M.
dc.date.accessioned2024-07-22T08:16:50Z
dc.date.available2024-07-22T08:16:50Z
dc.date.issued2014
dc.description.abstractBackground: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC).The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n = 298) received XELOX-Bev and Group 2 (n = 111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%) , stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95%CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95%CI; 16.8-23.1) for Group 2 (p = 0.036). Median PFS was 9.6 months (range 2-36 months, 95%CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95%CI; 7.4-10.5) for Group 2 (p = 0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p < 0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.
dc.identifier.DOI-ID10.7314/APJCP.2014.15.23.10375
dc.identifier.issn15137368
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16896
dc.language.isoEnglish
dc.publisherAsian Pacific Organization for Cancer Prevention
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectAdult
dc.subjectAged
dc.subjectAngiogenesis Inhibitors
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBone Neoplasms
dc.subjectCamptothecin
dc.subjectCarcinoma
dc.subjectColonic Neoplasms
dc.subjectDeoxycytidine
dc.subjectFemale
dc.subjectFluorouracil
dc.subjectHumans
dc.subjectLeucovorin
dc.subjectLiver Neoplasms
dc.subjectLung Neoplasms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplasm Metastasis
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectangiogenesis inhibitor
dc.subjectantineoplastic agent
dc.subjectbevacizumab
dc.subjectcamptothecin
dc.subjectdeoxycytidine
dc.subjectfluorouracil
dc.subjectfolinic acid
dc.subjectmonoclonal antibody
dc.subjectadult
dc.subjectaged
dc.subjectanalogs and derivatives
dc.subjectBone Neoplasms
dc.subjectcarcinoma
dc.subjectColonic Neoplasms
dc.subjectcomparative study
dc.subjectfemale
dc.subjecthuman
dc.subjectLiver Neoplasms
dc.subjectLung Neoplasms
dc.subjectmale
dc.subjectmetastasis
dc.subjectmiddle aged
dc.subjectpathology
dc.subjectretrospective study
dc.subjectsecondary
dc.subjecttreatment outcome
dc.titleXELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: A retrospective study of the anatolian society of medical oncology
dc.typeArticle

Files

Collections

Scopus Koleksiyonu